Cutaneous amyloid is a biomarker in early ATTRv neuropathy and progresses across disease stages.

These findings have implications for understanding the earliest manifestations of the clinical phenotype of ATTRv-associated neuropathy, for the pathophysiological construct of disease staging, and for timing the introduction of disease-modifying therapy.